Cadrenal Therapeutics, Inc. Common Stock (United States) is listed on the Nasdaq and has a market capitalization of $2.69 million, with shareholders equity totaling $4.09 million.
The company employs approximately 5 people and operates in the Others sector, within the Others industry.
Over the past 12 months, Cadrenal Therapeutics, Inc. Common Stock reported $- in revenue, generating net income of $-11.54 million.
Key financial metrics include a P/E ratio of -0.23, a price-to-book (P/B) ratio of 0.66, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker CVKD.